# Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

> **NCT02215161** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 14 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Hormone-Resistant Prostate Cancer
- Metastatic Prostate Carcinoma in the Soft Tissue
- Prostate Carcinoma Metastatic in the Bone
- PSA Progression
- Stage IV Prostate Adenocarcinoma AJCC v7

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT02215161
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-02
- **Primary completion:** 2017-02-15
- **Final completion:** 2018-04-02
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Risk to benefit ratio is not acceptable
- **Last updated:** 2018-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215161, "Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02215161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*